• Rotigotine Hydrochloride: Dopamine D2/D3 Receptor Agonist in

  2026-07-02

  Rotigotine hydrochloride is a benchmark dopamine D2/D3 receptor agonist for elucidating motor and non-motor mechanisms in Parkinson’s disease models. Its robust receptor profile, proven workflow versatility, and translationally relevant dosing set it apart in both in vitro and in vivo neurodegenerative research.

• Smoothened Agonist (SAG): Precision Tools for Translational

  2026-07-02

  This thought-leadership article explores the mechanistic depth and strategic value of Smoothened Agonist (SAG), a potent Hedgehog signaling activator, for translational neuroscience and disease modeling. Highlighting new sex-dependent immune data, protocol best practices, and the evolving clinical horizon, it guides researchers through experimental and therapeutic landscapes while positioning APExBIO's SAG as a gold-standard reagent.

• IEM 1460: Advancing AMPA Blocker Science for Neuroprotection

  2026-07-01

  Explore how IEM 1460, a selective AMPA receptor blocker, is redefining neuroprotection research. This in-depth article uniquely analyzes mechanistic insights, assay optimization, and translational implications for neuroscience.

• SAG: Smoothened Receptor Agonist for Precision Pathway Activ

  2026-07-01

  Smoothened Agonist (SAG) empowers researchers with tunable Hedgehog pathway activation, enabling robust studies in neuroprotection, stem cell maintenance, and developmental biology. This guide delivers advanced workflows, troubleshooting insights, and evidence-backed parameters for leveraging SAG’s unique selectivity and potency in both in vitro and in vivo models.

• 3-Deazaneplanocin (DZNep): Applied Epigenetic Modulation Wor

  2026-06-30

  3-Deazaneplanocin (DZNep) empowers researchers to dissect and manipulate epigenetic regulation with exceptional precision, targeting both cancer stem cells and metabolic pathways. This guide delivers stepwise workflows, troubleshooting insights, and practical protocol enhancements for DZNep-based experimental design in oncology and metabolic research.

• Cisapride (R 51619): Redefining Cardiac Electrophysiology Re

  2026-06-30

  This thought-leadership article examines how Cisapride (R 51619), a dual-acting 5-HT4 receptor agonist and hERG channel inhibitor, is catalyzing innovation in cardiac electrophysiology research. By integrating mechanistic insights and strategic translational guidance, we explore the value of Cisapride in deep phenotyping, high-content screening with iPSC-derived cardiomyocytes, and predictive safety workflows. The discussion builds beyond typical product pages by articulating how Cisapride enables next-generation cardiac toxicity assessment and arrhythmia modeling, with links to the latest deep learning-enabled approaches.

• Crizotinib Hydrochloride: ALK Kinase Inhibitor for Tumor Mod

  2026-06-29

  Crizotinib hydrochloride is an ATP-competitive ALK kinase inhibitor used in advanced cancer biology research. It enables precise inhibition of ALK, c-Met, and ROS1 phosphorylation, empowering the study of oncogenic kinase pathways in patient-derived assembloid models. The compound’s high purity and solubility support reproducible experimental outcomes.

• 3X (DYKDDDDK) Peptide: Precision Tagging Meets Protein Stabi

  2026-06-29

  Discover how the 3X (DYKDDDDK) Peptide advances affinity purification and immunodetection of FLAG-tagged proteins by integrating cutting-edge insights into protein stability and autophagic regulation. This article offers a unique perspective on protocol design, bridging fundamental mechanisms with practical biotechnological workflows.

• Astrocyte-to-Motoneuron Reprogramming via Ascl1-Myt1l-Pou3f2

  2026-06-28

  This study demonstrates that a combination of four transcription factors—Ascl1, Myt1l, Pou3f2, and Isl1—can directly reprogram rat and human astrocytes into motoneuron-like cells. The findings offer a promising strategy for spinal cord injury repair and provide mechanistic insight into cell fate transitions relevant to regenerative medicine.

• Neuromedin S (rat): Technical Protocols for GPCR Assays

  2026-06-27

  Neuromedin S (rat) provides a chemically defined peptide agonist for controlled activation of neuromedin U receptor signaling in rat GPCR/G protein research. The product offers predictable ligand identity for in vitro or ex vivo assays but is not suitable for diagnostic, therapeutic, or in vivo applications. Stringent adherence to solubility and storage protocols is essential for maintaining assay reproducibility.

• Adenosine Triphosphate (ATP): Applied Workflows in Metabolic

  2026-06-26

  Harness the full spectrum of Adenosine Triphosphate (ATP) for metabolic pathway interrogation and purinergic receptor signaling assays. Discover evidence-driven protocols, troubleshooting strategies, and the latest insights bridging enzyme regulation and cellular energetics—empowering reproducible, high-impact research.

• Canagliflozin: SGLT2 Inhibitor Workflows for Renal Research

  2026-06-26

  Canagliflozin enables researchers to dissect renal glucose handling and mitochondrial remodeling in diabetic models, going far beyond glycemic endpoints. Here, we detail optimized protocols, troubleshooting tips, and the latest insights on mitochondrial mechanisms, equipping metabolic disease labs with actionable guidance.

• Ionic Regulation of Cancer Cell Stiffness via MRTFA-KCNMB1 A

  2026-06-25

  Gajda et al. uncover a novel regulatory pathway in which the MRTFA-KCNMB1 axis modulates cancer cell stiffness, influencing metastatic potential and immune evasion. Their findings highlight potassium channel activity as a therapeutic target for reducing metastasis by altering biophysical properties of tumor cells.

• Network Pharmacology of CEP in Nasopharyngeal Carcinoma: Ins

  2026-06-25

  This study leverages network pharmacology, molecular docking, and in vivo experiments to elucidate how Cepharanthine (CEP) inhibits nasopharyngeal carcinoma (NPC) via the EGFR/PI3K/AKT/mTOR pathway. The findings highlight novel multi-targeted mechanisms and provide a data-rich foundation for future cancer research and therapeutic strategies.

• Targeted mRNA Nanoparticles Repair the BBB After Stroke via

  2026-06-24

  This study introduces a lipid nanoparticle system for targeted delivery of mRNA encoding interleukin-10 to ischemic brain regions, effectively promoting microglia polarization toward a protective phenotype. The approach demonstrates significant restoration of the blood–brain barrier and resolution of neuroinflammation post-stroke, offering a translational advance for mRNA therapeutics in neuroprotection.

15359 records 1/1024 page Next 12345 下5页 Last page